Occupational HIV Postexposure Prophylaxis With Darunavir/r.

Trial Profile

Occupational HIV Postexposure Prophylaxis With Darunavir/r.

Phase of Trial: Phase III

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Darunavir/ritonavir (Primary) ; Efavirenz; Lopinavir/ritonavir; Nucleotide reverse transcriptase inhibitors; Zidovudine
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PEPDar
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
    • 01 Sep 2013 Primary endpoint 'Treatment-discontinuation' has been met.
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top